Our study also suggests that gastric cancer patients in the high GLUT3 expression group tended to have a higher TMEscore than those in the low expression group, and GLUT3 was also significantly correlated with a variety of immune cells in pan-cancer analysis. This evidence concerns the gene SLC2A3 and gastric cancer.